Biocon has announced that its European partner, Zentiva has received a Decentralized Procedure (DCP) approval for its complex formulation, Liraglutide, in the European Union (EU). The approval is for the generic versions of Victoza® to treat Type-2 Diabetes and Saxenda® used in the treatment of weight management. Liraglutide is a glucagen-like Peptide1- receptor agonist ( GLO-1 receptor agonist) and is also know as incretin mimetics. Developed by Novo Nordisk, it was first approved in Europe in 2009. The medicine works by increasing insulin release from the pancreas and decreases excessive glucagen release.

The approval is for the generic versions of Victoza® and Saxenda®